Immunoregulatory activity of adenosine and its role in human cancer progression

Expert Review of Clinical Immunology

Volumn 10, Issue 7, 2014, Pages 897-914

  Muller Haegele, Sylvia ^a   Muller, Laurent ^a,b   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

5 adenosine monophosphate; adenosine; adenosine deaminase; adenosine receptors; ATP; cancer; CD39 and CD73 expression; immune cells; inflammation; tumor immune escape; tumor microenvironment

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ALPHA INTERFERON; CAFFEINE; CD39 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 6; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PERFORIN; RANTES; SMALL INTERFERING RNA; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ADENOSINE RECEPTOR;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHEMOTAXIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR INTERACTION; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PARACRINE SIGNALING; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPIC PLASTICITY; PLEIOTROPY; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TARGET CELL; TUMOR CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY;

ADENOSINE; CELL PROLIFERATION; HUMANS; NEOPLASMS; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 84902688437     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.915739     Document Type: Review

References (155)

1. Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal 2013;9(4):491-540
2. Hoskin DW, Mader JS, Furlong SJ, et al. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008;32(3):527-35
3. Zhou X, Zhi X, Zhou P, et al. Effects of ecto-5-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 2007; 17(6): 1341-6
4. Long JS, Crighton D, O'Prey J, et al. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell 2013;50(3):394-406
5. Montesinos MC, Desai A, Chen JF, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol 2002;160(6):2009-18
6. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13(12):842-57
7. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 2010;185(4):1993-8
8. Linden J. Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway". Am J Physiol Cell Physiol 2006; 291(3):C405-6
9. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997;90(4): 1600-10
10. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;29(39):5346-58
11. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; 362(4-5):299-309
12. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4 +CD25highFOXP3+ regulatory T cells. J Biol Chem 2010;285(10):7176-86
13. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204(6):1257-65
14. Ryzhov S, Novitskiy SV, Goldstein AE, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 2011; 187(11):6120-9
15. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110(4):1225-32
16. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005;5(9):712-21
17. Unsworth CD, Johnson RG Jr. ATP compartmentation in neuroendocrine secretory vesicles. Ann N Y Acad Sci 1990;603:353-63.discussion 364-355
18. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006;27(4): 211-17
19. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007;28(9):465-72
20. Santos-Rodrigues AD, Grane-Boladeras N, Bicket A, Coe IR. Nucleoside transporters in the purinome. Neurochem Int 2014; Epub ahead to print
21. Decking UK, Schlieper G, Kroll K, Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 1997;81(2): 154-64
22. Antonioli L, Colucci R, La Motta C, et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets 2012;13(6): 842-62
23. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25(1): 33-9
24. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997;57(13): 2602-5
25. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46(2):143-56
26. Merighi S, Mirandola P, Varani K, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 2003;100(1):31-48
27. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995;96(4):1979-86
28. Kull B, Svenningsson P, Fredholm BB. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Mol Pharmacol 2000;58(4):771-7
29. Ryzhov S, Zaynagetdinov R, Goldstein AE, et al. Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. J Immunol 2008; 180(11):7212-20
30. Zaynagetdinov R, Ryzhov S, Goldstein AE, et al. Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. Am J Respir Cell Mol Biol 2010;42(5):564-71
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
33. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27(45): 5904-12
34. Frey AB, Monu N. Signaling defects in anti-tumor T cells. Immunol Rev 2008;222: 192-205
35. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1
36. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6(10):715-27
37. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013;1284:1-5
38. Pellegatti P, Raffaghello L, Bianchi G, et al. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008;3(7): e2599
39. Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 2011;71(17):5601-5
40. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012 2012;485156
41. Bastid J, Cottalorda-Regairaz A, Alberici G, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013;32(14):1743-51
42. Aliagas E, Vidal A, Texido L, et al. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm 2014 2014;509027
43. Ryzhov S, Novitskiy SV, Zaynagetdinov R, et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 2008;10(9):987-95
44. Gessi S, Merighi S, Sacchetto V, et al. Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808(5):1400-12
45. Merighi S, Varani K, Gessi S, et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 2001;134(6):1215-26
46. Madi L, Ochaion A, Rath-Wolfson L, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004;10(13):4472-9
47. Fishman P, Bar-Yehuda S, Ardon E, et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003;23(3A):2077-83
48. Khoo HE, Ho CL, Chhatwal VJ, et al. Differential expression of adenosine A1 receptors in colorectal cancer and related mucosa. Cancer Lett 1996;106(1):17-21
49. D'Ancona S, Ragazzi E, Fassina G, et al. Effect of dipyridamole, 5'-(N-ethyl)-carboxamidoadenosine and 1, 3-dipropyl-8-(2-amino-4-chlorophenyl)- xanthine on LOVO cell growth and morphology. Anticancer Res 1994;14(1A):93-7
50. Shaban M, Smith RA, Stone TW. Purine suppression of proliferation of Sertoli-like TM4 cells in culture. Cell Prolif 1995; 28(12):673-82
51. Saito M, Yaguchi T, Yasuda Y, et al. Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A (1) adenosine receptors. Cancer Lett 2010; 290(2):211-15
52. Woodhouse EC, Amanatullah DF, Schetz JA, et al. Adenosine receptor mediates motility in human melanoma cells. Biochem Biophys Res Commun 1998; 246(3):888-94
53. Mirza A, Basso A, Black S, et al. RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 2005;4(12):1355-60
54. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010;10(7):1019-35
55. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19(6):355-67
56. Zarek PE, Powell JD. Adenosine and anergy. Autoimmunity 2007;40(6):425-32
57. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006;103(35):13132-7
58. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006; 314(5806):1792-5
59. Cronstein BN, Daguma L, Nichols D, et al. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 1990;85(4):1150-7
60. Junger WG. Purinergic regulation of neutrophil chemotaxis. Cell Mol Life Sci 2008;65(16):2528-40
61. Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA 2013;110(36): 14711-16
62. Najar HM, Ruhl S, Bru-Capdeville AC, Peters JH. Adenosine and its derivatives control human monocyte differentiation into highly accessory cells versus macrophages. J Leukoc Biol 1990;47(5): 429-39
63. Csoka B, Selmeczy Z, Koscso B, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 2012;26(1):376-86
64. Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008;112(5):1822-31
65. Wilson JM, Ross WG, Agbai ON, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 2009;182(8): 4616-23
66. Ben Addi A, Lefort A, Hua X, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol 2008;38(6): 1610-20
67. Miller JS, Cervenka T, Lund J, et al. Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor. J Immunol 1999;162(12):7376-82
68. Xaus J, Valledor AF, Cardo M, et al. Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. J Immunol 1999;163(8):4140-9
69. Hoskin DW, Butler JJ, Drapeau D, et al. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 2002;99(3):386-95
70. Raskovalova T, Lokshin A, Huang X, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res 2006;36(1-3):91-9
71. Su Y, Huang X, Raskovalova T, et al. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008;57(11):1611-23
72. Raskovalova T, Huang X, Sitkovsky M, et al. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005;175(7):4383-91
73. Lokshin A, Raskovalova T, Huang X, et al. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res 2006;66(15):7758-65
74. Raskovalova T, Lokshin A, Huang X, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 2007;67(12):5949-56
75. Hasko G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007;113(2):264-75
76. Leonard EJ, Skeel A, Chiang PK, Cantoni GL. The action of the adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes. Biochem Biophys Res Commun 1978; 84(1):102-9
77. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000;14(13):2065-74
78. Link AA, Kino T, Worth JA, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000;164(1): 436-42
79. Ryzhov S, Zaynagetdinov R, Goldstein AE, et al. Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther 2008;324(2):694-700
80. Buenestado A, Grassin Delyle S, Arnould I, et al. The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol 2010;159(6): 1304-11
81. Belikoff BG, Hatfield S, Georgiev P, et al. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol 2011;186(4):2444-53
82. Panther E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003;101(10): 3985-90
83. McColl SR, St-Onge M, Dussault AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J 2006;20(1):187-9
84. Hasko G, Szabo C, Nemeth ZH, et al. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157(10):4634-40
85. Le Moine O, Stordeur P, Schandene L, et al. Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996; 156(11):4408-14
86. Csoka B, Nemeth ZH, Selmeczy Z, et al. Role of A(2A) adenosine receptors in regulation of opsonized E. coli-induced macrophage function. Purinergic Signal 2007;3(4):447-52
87. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82
88. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005;174(2):1073-80
89. Mandapathil M, Whiteside TL. Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E(2) cooperation. Expert Opin Biol Ther 2011;11(9):1203-14
90. Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET. Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS One 2012; 7(2):e32416
91. Mosenden R, Tasken K. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell Signal 2011;23(6):1009-16
92. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414(6866):916-20
93. Gessi S, Varani K, Merighi S, et al. Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 2004;65(3): 711-19
94. Naganuma M, Wiznerowicz EB, Lappas CM, et al. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 2006;177(5):2765-9
95. Eppell BA, Newell AM, Brown EJ. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro. Implications for regulation of phagocytosis. J Immunol 1989;143(12): 4141-5
96. Salmon JE, Brogle N, Brownlie C, et al. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol 1993;151(5): 2775-85
97. Zalavary S, Stendahl O, Bengtsson T. The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. Biochim Biophys Acta 1994;1222(2):249-56
98. Minguet S, Huber M, Rosenkranz L, et al. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol 2005; 35(1):31-41
99. Chen LC, Delgado JC, Jensen PE, Chen X. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol 2009;183(6):4094-102
100. Griffin DO, Rothstein TL. Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol Med 2012;18: 1003-8
101. Biragyn A, Lee-Chang C. A new paradigm for an old story: the role of regulatory B cells in cancer. Front Immunol 2012;3:206
102. Saze Z, Schuler PJ, Hong CS, et al. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 2013;122(1):9-18
103. Rittiner JE, Korboukh I, Hull-Ryde EA, et al. AMP is an adenosine A1 receptor agonist. J Biol Chem 2012;287(8):5301-9
104. Szajnik M, Czystowska M, Szczepanski MJ, et al. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010;5(7):e11469
105. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9(3): 162-74
106. Kotsakis A, Harasymczuk M, Schilling B, et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012; 381(1-2):14-22
107. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59(10): 1593-600
108. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166(1):678-89
109. Mandapathil M, Szczepanski M, Harasymczuk M, et al. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012;1(5):659-69
110. Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012;42(7):1876-85
111. Whiteside TL, Jackson EK. Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol 2013;4:212
112. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010;285(36):27571-80
113. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol 2013;171(1):1-7
114. Massague J. TGFbeta in Cancer. Cell 2008; 134(2):215-30
115. Sitkovsky M, Lukashev D, Deaglio S, et al. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008; 153(Suppl 1):S457-64
116. Ben-Shoshan J, Maysel-Auslender S, Mor A, et al. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008;38(9):2412-18
117. Feoktistov I, Ryzhov S, Zhong H, et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004;44(5):649-54
118. Fishman P, Bar-Yehuda S, Synowitz M, et al. Adenosine receptors and cancer. Handb Exp Pharmacol 2009(193):399-441
119. Merighi S, Benini A, Mirandola P, et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 2006;72(1):19-31
120. Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 2013; 110(27):11091-6
121. Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 2006; 16(3):213-22
122. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010;107(4):1547-52
123. Wang L, Zhou X, Zhou T, et al. Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008; 134(3):365-72
124. Cekic C, Sag D, Li Y, et al. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 2012;188(1): 198-205
125. Madi L, Bar-Yehuda S, Barer F, et al. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278(43):42121-30
126. Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 2008;33(2):287-95
127. Gessi S, Merighi S, Varani K, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol 2007;211(3):826-36
128. van Troostenburg AR, Clark EV, Carey WD, et al. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004;42(10):534-42
129. Iwatsubo K, Okumura S, Ishikawa Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 2006;6(3): 239-47
130. Duan B, Davis R, Sadat EL, et al. Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice. J Immunol 2010;185(1):335-44
131. Saldou N, Obernolte R, Huber A, et al. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal 1998;10(6): 427-40
132. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
133. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
134. Liaudet L, Mabley JG, Pacher P, et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg 2002;235(4): 568-78
135. Hasko G, Sitkovsky MV, Szabo C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 2004;25(3):152-7
136. Glander P, Hambach P, Liefeldt L, Budde K. Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clin Chim Acta 2012;413(17-18):1391-7
137. Williams BA, Manzer A, Blay J, Hoskin DW. Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Biochem Biophys Res Commun 1997; 231(2):264-9
138. Harish A, Hohana G, Fishman P, et al. A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 2003; 23(4):1245-9
139. Khoa ND, Montesinos MC, Reiss AB, et al. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 2001;167(7):4026-32
140. Salmon JE, Cronstein BN. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 1990;145(7):2235-40
141. Zhao ZQ, Sato H, Williams MW, et al. Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol 1996; 271(4 Pt 2):H1456-64
142. Jordan JE, Thourani VH, Auchampach JA, et al. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol 1999;277(5 Pt 2):H1895-905
143. Felsch A, Stocker K, Borchard U. Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. J Immunol 1995; 155(1):333-8
144. Firestein GS, Bullough DA, Erion MD, et al. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J Immunol 1995;154(1):326-34
145. Thiel M, Chouker A. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-alpha of endotoxin-stimulated human polymorphonuclear leukocytes. J Lab Clin Med 1995;126(3):275-82
146. Krump E, Lemay G, Borgeat P. Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol 1996;117(8):1639-44
147. Krump E, Picard S, Mancini J, Borgeat P. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med 1997; 186(8):1401-6
148. Pouliot M, Fiset ME, Masse M, et al. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol 2002; 169(9):5279-86
149. Cadieux JS, Leclerc P, St-Onge M, et al. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci 2005; 118(Pt 7):1437-47
150. Sevigny CP, Li L, Awad AS, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol 2007;178(7):4240-9
151. Averill LE, Stein RL, Kammer GM. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 1988;115(1):88-99
152. Kizaki H, Suzuki K, Tadakuma T, Ishimura Y. Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. J Biol Chem 1990;265(9): 5280-4
153. Houslay MD, Kolch W. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 2000; 58(4):659-68
154. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12(6):258-66
155. Ryzhov S, Goldstein AE, Matafonov A, et al. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004; 172(12):7726-33